H. RES. 1287

Of inquiry directing the President to provide certain documents in the President’s possession to the House of Representatives relating to the recall of infant formula manufactured by Abbott Laboratories and potential impacts on the infant formula supply chain.

IN THE HOUSE OF REPRESENTATIVES

JULY 26, 2022

Mr. WALBERG submitted the following resolution; which was referred to the Committee on Energy and Commerce

RESOLUTION

Of inquiry directing the President to provide certain documents in the President’s possession to the House of Representatives relating to the recall of infant formula manufactured by Abbott Laboratories and potential impacts on the infant formula supply chain.

Resolved, That not later than 14 days after the adoption of this resolution, the President is directed to furnish to the House of Representatives copies of any document or record, audio recording, memorandum, call log, correspondence (electronic or otherwise), or other communication in the President’s possession (or any portion thereof), that refers or relates to the following:
(1) the memoranda and report referenced in the testimony given by Dr. Robert Califf on May 25, 2022, during the hearing related to the recall of infant formula manufactured by Abbott Laboratories and potential impacts on the infant formula supply chain held by the Committee on Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce of the House of Representatives;

(2) all communications between the Commissioner of Food and Drugs and other staff of the Food and Drug Administration and the White House regarding the infant formula recall and potential impact during or before February 2022;

(3) the failure of the Food and Drug Administration to ensure the whistleblower complaint submitted to the Food and Drug Administration by an employee of Abbott Laboratories was sent to all necessary and appropriate officials and what actions the Food and Drug Administration has taken to prevent such a failure from happening in the future;

(4) the number of full-time equivalent positions in the Office of Regulatory Affairs of the Food and Drug Administration that remain vacant for food safety compliance and inspection staff;
(5) all communications between the Food and Drug Administration and the Department of Agriculture about the recall of infant formula manufactured by Abbott Laboratories and the potential impact on the Special Supplemental Nutrition Program for Women, Infants, and Children, including the timing of such communications; and

(6) the number of submissions pending at the Food and Drug Administration as of the date of the adoption of this resolution for the marketing of infant formula, delineated by domestic and foreign manufacturers.